Chiron Halts Menjugate Meningococcal Vaccine Program After Pivotal Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trials were “successfully concluded,” but there are no plans to file a BLA for the meningococcal C conjugate vaccine due to limited commercial viability, Chiron says. The company plans to begin Phase III trials for its quadravalent meningococcal vaccine in 2005.